• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Abbott touts global launch of 1st-of-its-kind bioresorbable drug-eluting stent

Abbott touts global launch of 1st-of-its-kind bioresorbable drug-eluting stent

September 26, 2012 By MassDevice staff

Abbott logo

Right on schedule, Abbott (NYSE:ABT) touted the launch of its Absorb device, which it calls the world’s first drug eluting bioresorbable vascular scaffold.

Absorb, which won CE Mark approval in the European Union in January 2011, is now available across Europe and in parts of Asia Pacific and Latin America, the company announced yesterday. The healthcare giant had stated previously that it would launch commercially by the end of 2012.

Abbott consultant and Netherlands cardiologist Dr. Patrick Serruys waxed poetic about the potential for a fully resorbable stent system.

"This innovation represents a true paradigm shift in how we treat coronary artery disease," Serruys said in an Abbott statement released to the media. "With the launch of Absorb, a scaffold that disappears after doing its job is no longer a dream, but a reality."

Absorb, like other stents, works by opening up and providing support to clogged arteries. Unlike its metal counterparts, however, the device is designed to dissolve within approximately 2 years of implantation.

The device is comprised of polylactide, a bio-compatible substance used in medical implants such as resorbable sutures. Because it eventually disappears, the necessity to treat stent recipients with long-term dual anti-platelet therapy "may be reduced," according to a press release.

Abbott touts the device a world 1st but several other companies are hot on its heels, including San Diego-based Reva Medical, French device maker Arterial Remodeling Technologies and MultiCell Technologies Inc. (OTC:MCET).

Late last month Elixir Medical won CE Mark approval in the European Union for its partially resorbable DESyne BD drug-eluting stent, which features ultra-thin polymer coating that enables sustained drug release and degrades over 6 to 9 months, leaving behind a bare metal cobalt chromium stent.

Medical device titan Boston Scientific’s (NYSE:BSX) working on its own partially resorbable Synergy stent system, which incoming CEO Michael Mahoney – currently listed as president – predicted may win CE Mark as early as this year.

Filed Under: News Well Tagged With: Abbott, Bioabsorbable Stents

More recent news

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Endogenex data supports type 2 diabetes procedure
  • Ambu wins FDA clearance for first single-use cysto-nephroscope

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy